Venture Kick is a private philanthropic initiative based in Zurich, Switzerland, founded in 2007 to support Swiss startups at the pre-seed stage. It provides up to 150,000 Swiss francs in funding and offers structured entrepreneurial training aimed at developing sustainable businesses. Entrepreneurs participate in a competitive process, pitching their ideas up to three times for increasing funding amounts, while receiving valuable feedback from expert juries. To date, Venture Kick has supported 600 startup projects with a total of 24.9 million francs, leading to the incorporation of 454 active companies that have created over 6,000 jobs and attracted approximately 2.49 billion francs in subsequent investments. Companies founded by Venture Kick alumni have notably achieved significant recognition, with 55 percent of the TOP 100 Swiss Startup Award in 2018 represented by these ventures. In 2019, the initiative aimed to allocate 4.35 million francs to support idea-stage projects, facilitating the transition of Swiss scientific innovations to global markets.
Carewell is influencing the way people work in healthcare by providing flexible digital solutions tailored to their specific needs.
Scanvio
Grant in 2025
Scanvio offers AI-augmented ultrasound software for faster endometriosis diagnosis, providing expert sonography skills to gynecologists, improving health and surgical education.
Azure Cell Therapies
Grant in 2024
Azure Cell Therapies is a biotech company developing next-gen CGTs for neurodegenerative diseases
BLEEDnFIRE Therapeutics
Grant in 2024
BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments
Translation-X
Pre Seed Round in 2024
Translation-X is a biotechnology company specializing in the development of innovative therapeutics for Autism Spectrum Disorders (ASD). It employs a precision medicine strategy to target core symptoms of ASD, such as social interaction difficulties, aiming to provide effective treatment options for affected individuals.
ValTech Lifesciences
Grant in 2024
ValTech Lifesciences is a medtech startup promoting cardiovascular health through its proprietary heart valve characteristics that improve the performance of mechanical and biological prostheses.
Deegtal
Grant in 2024
dEEGtal’s use of AI to expedite epilepsy diagnosis could make a significant difference in patient care, by analyzing EEG data quickly, it might help identify patterns or anomalies that could be missed by human reviewers alone.
Regenosca
Pre Seed Round in 2024
Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.
TrueYouOmics
Convertible Note in 2024
TrueYouOmics specializes in comprehensive blood testing services, leveraging multi-omics and artificial intelligence to identify disease risks and facilitate preventive health planning. The company's innovative approach involves analyzing an individual's DNA, RNA, and protein data, then integrating these insights with medical knowledge graphs to estimate personalized disease risks. This holistic health assessment empowers individuals to proactively manage their well-being by taking preventive measures.
Isospec Analytics
Pre Seed Round in 2024
Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing to its clients.
Pace Locator
Grant in 2024
Pace Locator is a medical technology company that specializes in developing advanced imaging software. Its flagship product, also named Pace Locator, uses electrocardiogram (ECG) and echocardiogram (ECHO) data to generate 3D maps of the heart. This innovative tool helps healthcare professionals localize the source of cardiac arrhythmias and visualize the location of cardiac implantable electronic device (CIED) leads, enabling faster and more accurate diagnoses.
HeroSupport
Grant in 2023
HeroSupport is a medical device manufacturing company based in Veyrier, Geneva, established in 2019. The company specializes in creating personalized solutions that transform imaging and treatment tables into medical immobilization devices designed to enhance patient comfort during clinical procedures. By providing tailored support, these devices allow patients to receive prone breast radiotherapy without the need to adapt to the standard table setup. This innovation not only improves patient comfort but also aims to enhance the effectiveness and cost efficiency of cancer treatment for healthcare providers.
Transpire Bio
Grant in 2023
Transpire Bio is a biotechnology platform focused on the development of inhaled therapeutics aimed at improving global health. The company specializes in creating lower-cost generic alternatives for injectable drugs, enhancing patient access to essential medications. Its portfolio includes medicines and inhalation therapies designed for treating lung diseases as well as systemic conditions, utilizing a painless delivery method to improve patient experience and adherence to treatment. Through its innovative approach, Transpire Bio seeks to make significant advancements in the field of inhalation therapies.
AlpineWell
Grant in 2023
AlpineWell developing novel solutions to hunger and swallowing difficulties, AlpineWell produces patient-centric food for special medicinal purposes (FSMP) and also provides automatic nutrition tracking to detect malnutrition early on.
Isospec Analytics
Grant in 2023
Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing to its clients.
Rhovica Neuroimaging
Grant in 2022
Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
Ocumeda
Grant in 2022
Ocumeda is a telemedical network specializing in ophthalmology, providing accessible eye examinations through collaborations with opticians, retirement homes, and various companies. The company's services include remote assessments conducted by board-certified ophthalmologists, utilizing a secure cloud platform and advanced medical artificial intelligence to enhance the screening process. This approach aims to enable opticians and pharmacies to effectively detect blindness and prevent vision loss, ensuring that individuals receive timely and accurate eye care.
Sensawear
Grant in 2022
Sensawear is a medical technology company that specializes in the production of wearable, textile-integrated sensors. These sensors monitor tissue oxygenation and skin pressure in real-time, alerting users to potential pressure injuries before they occur. By providing early warnings of low-oxygenation conditions caused by high-pressure points, Sensawear's products enable users to take preventative action, such as moving or being moved, thus minimizing the risk of painful and dangerous pressure ulcers.
SightIn Health
Grant in 2022
SightIn Health is a Swiss company founded in 2021 that specializes in artificial intelligence-powered software for portable ultrasound devices. The firm has developed an imaging platform that enhances the functionality of ultrasound machines by providing automated quality assessments, probe guidance, and image analysis. This technology aims to reduce the skill barrier traditionally associated with ultrasound equipment, making it easier for healthcare providers to capture and interpret medical images. By improving the accuracy of medical diagnostics and prognostics, SightIn Health supports healthcare companies in delivering better patient care.
Maven Health
Non Equity Assistance in 2022
Maven Health is a health tech company that provides an end-to-end metabolic health solution designed for healthcare providers. It specializes in assessing individuals' metabolic health using saliva as the bio-fluid for metabolite measurements. These measurements are analyzed with advanced Nuclear Magnetic Resonance (NMR) spectrometers employing custom analytical methods. The system is designed to be minimally invasive and cost-effective, assisting healthcare professionals in identifying at-risk individuals who may not be recognized through traditional healthcare practices. The results are delivered through an intuitive data platform, facilitating better decision-making and patient care.
FimmCyte
Grant in 2022
FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on endometriosis. The company aims to accelerate the journey toward effective cures by addressing significant healthcare needs and introducing novel solutions that enhance women's health. FimmCyte is dedicated to empowering women to take control of their health and tackle unmet medical needs associated with these conditions.
SURI BioTech
Grant in 2022
Suri BioTech is a biotechnology company focused on developing health-promoting bacterial strains aimed at alleviating bloating and intestinal discomfort. The company specializes in creating science-based probiotics, particularly for infant health, utilizing proprietary strains that reduce hydrogen gas production by intestinal microorganisms. This innovative approach has potential applications in various functional gastrointestinal disorders, including infant colic and lactose intolerance. By leveraging its biotech platform, Suri BioTech seeks to provide effective solutions for individuals suffering from gastrointestinal issues.
Isospec Analytics
Grant in 2022
Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing to its clients.
OptimaRatio
Grant in 2022
OptimaRatio liberates chronic and rare disease patients from managing their complex health data.
NALU Health
Grant in 2022
NALU Health specializes in digital health solutions for women's reproductive health. It offers a software application that tracks menstrual cycles and provides personalized, hormone-free therapies to manage conditions like menstrual pain, endometriosis, and irregular periods, including amenorrhea and polycystic ovary syndrome (PCOS). The platform aims to empower women to naturally regulate their menstrual cycles and improve overall menstrual health.
NextImmune
Grant in 2022
NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.
YLAH
Grant in 2022
YLAH specializes in creating web and mobile applications tailored for psychotherapists and their patients. The company focuses on developing technology that delivers individualized therapies, clinical assessments, and health monitoring. This digital tool enables therapists to enhance and scale their services effectively, improving the overall therapeutic experience for patients.
Rhovica Neuroimaging
Grant in 2022
Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
Rhovica Neuroimaging
Grant in 2022
Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
Galventa
Convertible Note in 2022
Galventa is a company focused on enhancing sleep quality and wakefulness through the development of innovative galenic platform technologies. It produces a food supplement that utilizes micro-pellets designed for time-controlled release, specifically aimed at alleviating symptoms of sleep inertia. This product helps regulate the sleep-wake cycle and supports the synchronization of the circadian clock, enabling individuals who experience sleep inertia to align their sleep patterns with their daily activities. Through clinically tested solutions, Galventa addresses the challenges associated with sleep disruption, promoting better overall sleep health.
Sensemodi
Grant in 2022
Sensemodi develops an AI-powered smart wearable device that assesses joint health, particularly focusing on the knee and other joints. By utilizing a combination of thermal, acoustic, and kinematic data, the device provides a quick evaluation of joint conditions. This innovative technology aims to prevent disabilities and reduce the socioeconomic burden associated with musculoskeletal disorders. The wearable allows users to conveniently monitor their joint health, facilitating access to improved healthcare treatments and promoting proactive management of joint-related issues.
Adiposs
Seed Round in 2021
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.
Bottneuro
Grant in 2021
Bottneuro specializes in developing non-invasive therapies for patients with early to moderate-stage Alzheimer's Disease. The company utilizes its NENI technology platform to create stimulation protocols that employ electrical stimulation of neurons and glial cells in the brain. Additionally, Bottneuro's innovative brain therapy system incorporates plant-based components and features a 3D-printed cap designed for continuous monitoring and targeted delivery of active substances. This approach aims to address the specific needs of Alzheimer's patients, ultimately enhancing their quality of life and improving treatment outcomes.
Galventa
Convertible Note in 2021
Galventa is a company focused on enhancing sleep quality and wakefulness through the development of innovative galenic platform technologies. It produces a food supplement that utilizes micro-pellets designed for time-controlled release, specifically aimed at alleviating symptoms of sleep inertia. This product helps regulate the sleep-wake cycle and supports the synchronization of the circadian clock, enabling individuals who experience sleep inertia to align their sleep patterns with their daily activities. Through clinically tested solutions, Galventa addresses the challenges associated with sleep disruption, promoting better overall sleep health.
Resmonics
Grant in 2021
Resmonics, established in October 2020 as a spin-off from ETH Zürich and the University of St. Gallen, specializes in privacy-friendly acoustic artificial intelligence designed to analyze soundscapes in various environments. Its primary focus is on detecting symptoms of infectious lung diseases, particularly for chronic disease management and monitoring respiratory symptoms. The company's flagship product line, Quorum, integrates this AI technology with air quality sensors and noise analytics to foster healthy and productive working conditions. Additionally, Resmonics develops tools that provide objective, clinically validated insights into respiratory health, offering early warnings for potential crises and enhancing patient care through mobile applications.
CustomSurg
Grant in 2021
CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.
Neurosoft Bioelectronics
Seed Round in 2021
Neurosoft Bioelectronics specializes in the development of soft implantable electrodes designed to interface with the nervous system for diagnosing and treating neurological disorders. Based in Geneva, Switzerland, the company has created next-generation electrodes that are compliant and conformable, addressing the limitations of existing stiff devices. Their flagship product, SOFT ECoG, is a subdural electrode that records from and stimulates the brain's surface, enhancing recording quality and minimizing MRI artifacts. Neurosoft's technology promotes long-term bio-integration, adapting to both static and dynamic mechanics of neural tissue, which can improve therapeutic outcomes for patients and expand the applications of neural interfaces in clinical settings.
Rea Diagnostics
Pre Seed Round in 2020
Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.
Regenosca
Pre Seed Round in 2020
Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.
CustomSurg
Convertible Note in 2020
CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.
Aseptuva
Grant in 2020
Aseptuva is an early-stage MedTech startup located in Technopark Winterthur, dedicated to addressing Healthcare-Associated Infections (HAI) that arise from catheter use in healthcare facilities. Catheters, essential for delivering medications, are often contaminated with pathogens, leading to severe complications such as pneumonia and bloodstream infections, which result in significant mortality and substantial healthcare costs. To combat this issue, Aseptuva is developing innovative medical devices designed for in-situ disinfection of various catheters, aiming to prevent infections before they occur. The company’s technology offers a robust automated system that assists medical staff, ultimately helping hospitals reduce the incidence of infections and save lives. Aseptuva aspires to establish a new standard in critical care, positively influencing millions of patients worldwide.
CustomSurg
Grant in 2020
CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.
Axentless
Grant in 2020
Axentless develops software using advanced algorithmic technologies to enable interactive speech therapy practice for stroke victims.
LifeMatrix
Grant in 2020
LifeMatrix specializes in the development of biomimetic implants and bio-engineering technology aimed at treating cardiovascular diseases and facilitating the growth of human replacement tissues. The company creates human cell-derived, off-the-shelf tissue-engineered implants that transform into living tissue after implantation, allowing them to grow and regenerate alongside the patient. This innovative technology addresses the limitations of traditional implants and is designed to enhance patient recovery. LifeMatrix's award-winning solutions are founded on over 20 years of extensive research, supported by multiple national and international grants, and validated through more than 100 peer-reviewed publications. Preclinical studies have demonstrated the safety and efficacy of these implants, paving the way for their clinical application.
Helvitek Labs
Grant in 2020
Helvitek Labs, founded in 2019 and based in Lausanne, specializes in developing advanced anti-pollution face masks. The company was established by Théo-Tim Denisart, a graduate of the Swiss Federal Institute of Technology in Lausanne, and Roberto Costa, a former marketing director at Swatch, motivated by their experiences with severe air pollution in China. Helvitek Labs focuses on integrating artificial intelligence with innovative filtering and sealing technologies to improve mask comfort and effectiveness, particularly for health professionals who endure prolonged use of traditional respirators. Their efforts have garnered significant support, including recognition at the Start Lausanne contest and grants from the EPFL and the Vaud Foundation for Technological Innovation, which enabled the firm to establish itself within the EPFL Innovation Park and build a dedicated team. Officially incorporated as a public limited company in March 2020, Helvitek Labs aims to address the challenges associated with air quality and mask usage.
Adiposs
Pre Seed Round in 2020
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.
Emovo
Pre Seed Round in 2020
Emovo Care SA, founded in 2020 and located in Lausanne, Switzerland, develops a robotic hand orthosis aimed at individuals with motor impairments resulting from stroke. The company is ISO 13485 certified and focuses on creating accessible robotic devices that facilitate movement at home for hemiparetic stroke patients. Their flagship product is an active orthosis designed to enable users to move their hands independently, enhancing rehabilitation efforts. The device is accompanied by a mobile application that tracks usage and motivates users, thereby providing value to patients, clinicians, and health insurers. The core technology behind the orthosis emerged from research conducted during a PhD program at EPFL, which garnered significant international media attention for its innovative approach to brain-computer interfaces. The product is expected to receive CE marking by 2022.
Nutrix
Grant in 2020
Nutrix is a Swiss health-tech company founded in 2019 and based in Basel. It specializes in developing a nanosensor that is placed on the tooth to measure glucose levels in saliva, providing a non-invasive method for users to monitor their health. This technology is integrated with an external application that tracks food intake and offers dietary advice, aiming to aid in the prevention of diabetes. Nutrix combines artificial intelligence with wearables to create cost-effective healthcare solutions. In 2025, the company plans to introduce CortiSense, a non-invasive cortisol monitoring sensor that has already received a CES Innovation Award, further expanding its portfolio of health monitoring technologies. Through its innovative approach, Nutrix enables users to manage their health conditions effectively without the need for frequent medical consultations.
Flowbone
Grant in 2020
Flowbone is a company based in Lausanne, Switzerland, specializing in injectable biomaterials designed for the minimal-invasive augmentation of fragile bones that are at high risk of fracture. Its innovative technology stimulates the body's self-healing capabilities, allowing for local repair of bone and restoration of natural strength without compromising bone mechanics or blood flow. Flowbone focuses on addressing the needs of patients suffering from chronic insufficiency fractures and aims to enhance bone health, particularly in spine surgery. The company envisions a future where the elderly can maintain a high level of independence and quality of life, free from the debilitating effects of fragility fractures.
Regenosca
Grant in 2020
Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.
MimiX Biotherapeutics
Grant in 2020
MimiX Biotherapeutics Sàrl, established in 2016 and based in La Tène, Switzerland, specializes in the development of biofabrication technology for therapeutic and diagnostic applications. The company focuses on creating an ultra-fast biomanufacturing process that enables the production of patient-specific biological tissue equivalents. This innovative approach supports regenerative medicine and personalized healthcare, allowing for tailored treatments that meet individual patient needs. By advancing tissue engineering techniques, MimiX Biotherapeutics aims to enhance the precision and effectiveness of medical interventions.
STIMIT
Pre Seed Round in 2020
STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.
Genknowme
Pre Seed Round in 2020
GenKnowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By measuring DNA methylation biomarkers, the company provides insights into how diet, physical activity, tobacco use, and alcohol consumption influence individual health. GenKnowme aims to transform scientific research into practical applications, allowing health-conscious individuals to better understand their genetic predispositions and make informed lifestyle choices for proactive health management.
SurgeonsLab
Grant in 2020
SurgeonsLab, founded in 2020 and based in Bern, Switzerland, specializes in developing patient-specific training models for surgical procedures and the validation of new medical devices. The company focuses on microsurgical treatment planning and strategy, providing tools that enhance the training experience for medical professionals. By utilizing advanced technology, SurgeonsLab's products facilitate testing and planning for surgical interventions, significantly improving patient safety and outcomes. The company's innovative approach offers an alternative to traditional human and animal models, thereby enhancing the learning curve for medical trainees.
EarlySight
Grant in 2020
EarlySight SA is a Swiss company, established in 2016 and based in Lausanne, that focuses on developing innovative medical devices for the early detection and treatment of eye diseases. The company has created an advanced eye fundus camera that enhances retinal imaging through precise illumination and real-time correction of ocular aberrations. This device utilizes cellular-level imaging technology to identify subtle structural changes in the retina, allowing for effective monitoring of treatment outcomes in a quick and non-invasive manner. By facilitating the visualization of cell morphology within the retina, EarlySight aims to improve the capabilities of eye specialists in diagnosing and managing ocular conditions.
Inanna Fertility
Grant in 2020
Inanna Fertility specializes in developing clinical decision support solutions specifically for fertility clinics, focusing on enhancing the outcomes of in-vitro fertilization treatments. The company offers a groundbreaking algorithm-based platform that integrates machine learning and a comprehensive patient database to deliver personalized treatment recommendations. This platform is designed to dynamically adjust based on each patient's medical history and treatment responses, providing physicians with critical insights to inform their decisions. By leveraging this technology, Inanna Fertility aims to reduce the physical, emotional, and financial burdens faced by couples undergoing fertility treatments, ultimately improving their overall experience and success rates in achieving pregnancy.
Terapet
Grant in 2020
Terapet SA, founded in 2019 in Geneva, Switzerland, specializes in proton therapy, an advanced form of radiotherapy for cancer treatment. Established by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals, the company aims to provide precise tumor targeting while minimizing damage to adjacent healthy tissues. Terapet's innovative technology allows for a reduced radiation dose to surrounding healthy cells by administering high doses of protons that halt at specific depths within the patient. This capability enables medical professionals to monitor the proton dose in real-time and in three dimensions, making cancer treatment more effective and potentially more cost-efficient. The company has successfully demonstrated the feasibility of its concept and is in the process of developing an initial version for market launch.
Neurosoft Bioelectronics
Grant in 2020
Neurosoft Bioelectronics specializes in the development of soft implantable electrodes designed to interface with the nervous system for diagnosing and treating neurological disorders. Based in Geneva, Switzerland, the company has created next-generation electrodes that are compliant and conformable, addressing the limitations of existing stiff devices. Their flagship product, SOFT ECoG, is a subdural electrode that records from and stimulates the brain's surface, enhancing recording quality and minimizing MRI artifacts. Neurosoft's technology promotes long-term bio-integration, adapting to both static and dynamic mechanics of neural tissue, which can improve therapeutic outcomes for patients and expand the applications of neural interfaces in clinical settings.
Testmate Health
Grant in 2020
Testmate Health is a medtech startup and an award-winning spin-off of the University of Geneva, focused on developing innovative healthcare solutions. The company has created a smartphone-compatible test kit that can diagnose diseases with identifiable DNA or RNA sequences, providing results directly at home in just minutes. Its first product is a rapid urine self-test for the four most common sexually transmitted diseases, addressing the urgent need for timely diagnosis, as one million new STDs are diagnosed daily. Traditional testing often requires lab work and can take up to seven days for results. Testmate Health's all-in-one kit is designed for ease of use, allowing users to obtain immediate results that can be scanned by a smartphone for quick access to treatment if necessary. The company is also working on additional test kits for other diseases, aiming to empower individuals to manage their health conveniently from home.
deepCDR Biologics
Pre Seed Round in 2020
deepCDR Biologics AG is a biotechnology company based in Basel, Switzerland, founded in 2018. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on the development of innovative biologics, deepCDR Biologics aims to enhance the effectiveness of therapeutic antibodies in the pharmaceutical industry.
Swiss Medical Union
Grant in 2020
Swiss Medical Union SA, founded in 2019 and based in Yverdon-les-Bains, Switzerland, specializes in healthcare technology focused on testing the interaction, efficiency, and safety of new medical products. The company manufactures Micro-Bioreactor equipment that allows for ex vivo testing with human organ and tissue models, enabling the selection of appropriate therapies tailored to individual patient needs. Additionally, Swiss Medical Union develops software that simulates organ activity, analyzes interactions between medical products and specific organs, and monitors real-time effects of treatments within the circulatory system. The company also provides clinical testing services aimed at supporting healthcare professionals in making informed clinical decisions, particularly in cancer treatment. Its offerings are designed to enhance therapeutic outcomes while minimizing the risks associated with unnecessary treatments.
deepCDR Biologics
Grant in 2020
deepCDR Biologics AG is a biotechnology company based in Basel, Switzerland, founded in 2018. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on the development of innovative biologics, deepCDR Biologics aims to enhance the effectiveness of therapeutic antibodies in the pharmaceutical industry.
autonomyo
Grant in 2020
Autonomyo is a Swiss company, founded in 2014 and based in Lausanne, that specializes in developing robotic rehabilitation solutions aimed at enhancing mobility for individuals with neurological gait disorders. The company offers a lightweight exoskeleton designed for robotically assisted gait training, which can be utilized in rehabilitation clinics as well as in home settings with remote monitoring capabilities. This technology is intended to increase accessibility and training intensity for users, enabling healthcare professionals to better support individuals with neuromuscular and motor disorders in regaining their freedom of movement. Autonomyo's team comprises engineers, developers, and healthcare professionals who are dedicated to improving the quality of life for those affected by gait impairments.
C-MedTec
Grant in 2020
C-MedTec is focused on developing a diagnostic helmet that enhances the detection and monitoring of brain concussions, addressing a critical gap in current medical practices. Traditional methods rely on subjective assessments performed by trained professionals, leaving a void in timely diagnosis and proper care. The innovative helmet measures brain metabolism and identifies abnormal neurological behavior following head trauma, facilitating early detection and diagnosis. This advancement aims to provide medical centers and sports organizations with the necessary tools to promote safer sporting practices and reduce the risk of long-term effects associated with repeated brain injuries, such as Alzheimer's disease and chronic traumatic encephalopathy (CTE).
Galventa
Grant in 2020
Galventa is a company focused on enhancing sleep quality and wakefulness through the development of innovative galenic platform technologies. It produces a food supplement that utilizes micro-pellets designed for time-controlled release, specifically aimed at alleviating symptoms of sleep inertia. This product helps regulate the sleep-wake cycle and supports the synchronization of the circadian clock, enabling individuals who experience sleep inertia to align their sleep patterns with their daily activities. Through clinically tested solutions, Galventa addresses the challenges associated with sleep disruption, promoting better overall sleep health.
KOVE medical
Grant in 2019
KOVE is a MedTech company focused on enhancing fetal treatment outcomes by addressing the risks associated with fetoscopic procedures. The company has developed an innovative implantable medical device designed to close the openings created in the fetal membrane during these treatments. By securing these holes, KOVE's device helps prevent membrane rupture, which can lead to premature delivery. This advancement enables healthcare providers to perform more fetal interventions safely, ultimately aiming to improve the chances of successful outcomes for unborn children.
Pregnolia
Grant in 2019
Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, enabling early intervention to prolong gestation and enhance neonatal health outcomes. Pregnolia serves pregnant women and gynecologists, aiming to ensure every woman experiences a happy, healthy, and informed pregnancy. The company's dedicated team, including Sabrina, Francisco, and Annette, is committed to completing clinical trials, navigating regulatory paths, and commercializing the device to support gynecologists in improving preterm birth risk assessment and management.
Adiposs
Pre Seed Round in 2019
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.
anavo medical
Grant in 2019
Anavo Medical specializes in developing nanoparticle-based pharmaceutical products aimed at enhancing wound healing and minimizing complications associated with skin grafts. The company's innovative formulation utilizes bioactive nanoparticles suspended in a user-friendly matrix, incorporating active ingredients such as metal oxide nanoparticles. These components possess anti-inflammatory and neo-angiogenic properties, which stimulate blood vessel regeneration and mitigate inflammation. By leveraging advanced nanotechnology, Anavo Medical's products empower healthcare professionals to improve patient outcomes, ensuring safer surgeries and promoting faster recovery for individuals undergoing skin transplantation procedures.
frater.swiss
Seed Round in 2019
Frater.swiss specializes in the development and production of innovative devices and applications designed for out-of-hospital care, specifically targeting hypothermic patients. Their products are utilized by healthcare professionals in high-pressure environments, including emergency medicine, expedition medicine, military medicine, and veterinary medicine. The company's focus is on creating efficient solutions for measuring hypothermia and stabilizing patient temperature through warm infusion, ultimately enhancing the quality of care in critical situations. By equipping medical personnel with advanced tools, Frater.swiss aims to improve patient outcomes and facilitate life-saving interventions in emergencies.
Artiria Medical
Seed Round in 2019
Artiria Medical SA develops innovative micro-actuated devices aimed at treating vascular diseases, particularly in the brain. Founded in 2019 and based in Lausanne, Switzerland, the company focuses on enhancing the precision and control of surgical procedures involving catheters and guidewires. Its technology facilitates micromotion within brain arteries, thereby improving navigation during stroke treatments. By enabling surgeons to perform these complex procedures with greater accuracy, Artiria Medical contributes to better patient outcomes and the potential to save lives.
Auxivo
Seed Round in 2019
Auxivo AG is a company based in Zürich, Switzerland, specializing in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing strain and fatigue, Auxivo's exoskeletons enhance worker safety and overall well-being, helping to prevent injuries and improve productivity in the workplace. The company's focus on creating accessible and effective solutions aims to ensure that workers can perform their duties with greater ease and security.
OxyPrem
Pre Seed Round in 2019
OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.
OxyPrem
Seed Round in 2019
OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.
Alibion
Grant in 2019
Alibion AG, founded in 2018 and based in Allschwil, Switzerland, specializes in drug discovery and the development of therapeutics. The company addresses the challenge of bringing innovative therapies from academic laboratories to patients by accelerating early-stage development. Alibion focuses on identifying promising new therapeutics and collaborates with outsourced partners to streamline the development process, thereby minimizing time and costs while ensuring compliance with quality standards. By doing so, Alibion aims to enhance the availability of novel treatments, ultimately improving patient outcomes on a global scale.
Adiposs
Grant in 2019
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.
anavo medical
Grant in 2019
Anavo Medical specializes in developing nanoparticle-based pharmaceutical products aimed at enhancing wound healing and minimizing complications associated with skin grafts. The company's innovative formulation utilizes bioactive nanoparticles suspended in a user-friendly matrix, incorporating active ingredients such as metal oxide nanoparticles. These components possess anti-inflammatory and neo-angiogenic properties, which stimulate blood vessel regeneration and mitigate inflammation. By leveraging advanced nanotechnology, Anavo Medical's products empower healthcare professionals to improve patient outcomes, ensuring safer surgeries and promoting faster recovery for individuals undergoing skin transplantation procedures.
Araris Biotech
Pre Seed Round in 2019
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.
Invasight
Seed Round in 2019
Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.
STIMIT
Grant in 2019
STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.
Araris Biotech
Grant in 2019
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.
KOVE medical
Seed Round in 2019
KOVE is a MedTech company focused on enhancing fetal treatment outcomes by addressing the risks associated with fetoscopic procedures. The company has developed an innovative implantable medical device designed to close the openings created in the fetal membrane during these treatments. By securing these holes, KOVE's device helps prevent membrane rupture, which can lead to premature delivery. This advancement enables healthcare providers to perform more fetal interventions safely, ultimately aiming to improve the chances of successful outcomes for unborn children.
frater.swiss
Seed Round in 2019
Frater.swiss specializes in the development and production of innovative devices and applications designed for out-of-hospital care, specifically targeting hypothermic patients. Their products are utilized by healthcare professionals in high-pressure environments, including emergency medicine, expedition medicine, military medicine, and veterinary medicine. The company's focus is on creating efficient solutions for measuring hypothermia and stabilizing patient temperature through warm infusion, ultimately enhancing the quality of care in critical situations. By equipping medical personnel with advanced tools, Frater.swiss aims to improve patient outcomes and facilitate life-saving interventions in emergencies.
Artiria Medical
Seed Round in 2019
Artiria Medical SA develops innovative micro-actuated devices aimed at treating vascular diseases, particularly in the brain. Founded in 2019 and based in Lausanne, Switzerland, the company focuses on enhancing the precision and control of surgical procedures involving catheters and guidewires. Its technology facilitates micromotion within brain arteries, thereby improving navigation during stroke treatments. By enabling surgeons to perform these complex procedures with greater accuracy, Artiria Medical contributes to better patient outcomes and the potential to save lives.
Genknowme
Grant in 2019
GenKnowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By measuring DNA methylation biomarkers, the company provides insights into how diet, physical activity, tobacco use, and alcohol consumption influence individual health. GenKnowme aims to transform scientific research into practical applications, allowing health-conscious individuals to better understand their genetic predispositions and make informed lifestyle choices for proactive health management.
ALAnostics
Pre Seed Round in 2019
ALAnostics is a biopharmaceutical company that specializes in oncodiagnostics, originating as a spin-off from the University of Geneva. The company focuses on developing innovative tumour painting technology designed to assist surgeons in the real-time identification and removal of breast cancer during surgery. By utilizing nanomedicines for fluorescence-guided surgery, along with 5-ALA prodrugs for photodynamic therapy and light-activated antimicrobials, ALAnostics aims to enhance the accuracy of tumor removal, ultimately improving patient outcomes and saving lives.
Hi-D Imaging
Grant in 2019
Hi-D Imaging AG, founded in 2019 and based in Winterthur, Switzerland, specializes in a SaaS-based pre-operational planning platform tailored for cardiac procedures, particularly trans-catheter aortic valve implantation. The platform assesses the hemodynamics of patient-specific anatomies, allowing physicians to analyze blood flow patterns and perform in-vitro fluid dynamic analyses. This technology enables the selection of the optimal size and shape of heart valves, facilitating personalized solutions for patients with aortic stenosis before cardiac surgery. By streamlining pre-operational planning and enhancing data-driven decision-making, Hi-D Imaging aims to improve outcomes for patients with cardiovascular diseases while reducing the need for unnecessary medical imaging examinations. The company's AI-based cardiac image processing technology further supports medical professionals by producing detailed images of cardiac structures, thereby decreasing planning times and addressing the limitations of traditional medical scans.
Invasight
Grant in 2019
Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.
Auxivo
Pre Seed Round in 2019
Auxivo AG is a company based in Zürich, Switzerland, specializing in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing strain and fatigue, Auxivo's exoskeletons enhance worker safety and overall well-being, helping to prevent injuries and improve productivity in the workplace. The company's focus on creating accessible and effective solutions aims to ensure that workers can perform their duties with greater ease and security.
B-rayZ
Grant in 2019
B-rayZ is a spin-off from the University Hospital Zurich, focused on enhancing radiology through advanced technology. The team comprises experienced radiologists, data scientists, and physicians with over 15 years of expertise in medical imaging. B-rayZ develops artificial intelligence-based software that aids radiologists in mammography by offering real-time assessments of image quality and breast density. This innovative software enables accurate and standardized evaluations of medical imaging data, thereby improving breast cancer detectability. By providing intelligent tools, B-rayZ supports radiologists in enhancing their diagnostic capabilities while also contributing to reduced healthcare costs.
EraCal
Seed Round in 2019
EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.
KOVE medical
Grant in 2019
KOVE is a MedTech company focused on enhancing fetal treatment outcomes by addressing the risks associated with fetoscopic procedures. The company has developed an innovative implantable medical device designed to close the openings created in the fetal membrane during these treatments. By securing these holes, KOVE's device helps prevent membrane rupture, which can lead to premature delivery. This advancement enables healthcare providers to perform more fetal interventions safely, ultimately aiming to improve the chances of successful outcomes for unborn children.
Artiria Medical
Grant in 2019
Artiria Medical SA develops innovative micro-actuated devices aimed at treating vascular diseases, particularly in the brain. Founded in 2019 and based in Lausanne, Switzerland, the company focuses on enhancing the precision and control of surgical procedures involving catheters and guidewires. Its technology facilitates micromotion within brain arteries, thereby improving navigation during stroke treatments. By enabling surgeons to perform these complex procedures with greater accuracy, Artiria Medical contributes to better patient outcomes and the potential to save lives.
frater.swiss
Grant in 2019
Frater.swiss specializes in the development and production of innovative devices and applications designed for out-of-hospital care, specifically targeting hypothermic patients. Their products are utilized by healthcare professionals in high-pressure environments, including emergency medicine, expedition medicine, military medicine, and veterinary medicine. The company's focus is on creating efficient solutions for measuring hypothermia and stabilizing patient temperature through warm infusion, ultimately enhancing the quality of care in critical situations. By equipping medical personnel with advanced tools, Frater.swiss aims to improve patient outcomes and facilitate life-saving interventions in emergencies.
Positrigo
Seed Round in 2018
Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.
Resistell
Seed Round in 2018
Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.
OxyPrem
Grant in 2018
OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.
Prediva
Grant in 2018
Prediva SA, founded in 2019 and based in Cottens, Switzerland, develops predictive machine learning software for the diagnosis and treatment of coronary artery disease. The company's innovative platform integrates medical image analysis with machine learning models and computational fluid dynamics simulations to create personalized 3D models of coronary arteries. This technology allows for the prediction of plaque progression and offers recommendations for stent placement and treatment planning. By equipping clinicians with insightful patient analyses, Prediva enables evidence-based treatment decisions that aim to reduce costs, procedure times, and the need for invasive interventions.
Hemolytics
Grant in 2018
Hemolytics is a MedTech company focused on advancing malaria detection through the development of a medical diagnostic device. This innovative device utilizes a chemical amplification method to enhance the sensitivity of malaria detection, achieving a level ten times greater than existing malaria rapid diagnostic tests. By amplifying a pan-malarial biomarker with stable and inexpensive reagents, Hemolytics aims to provide a point of care test that allows for the early detection of malaria, ultimately improving patient outcomes and facilitating timely treatment.
Aspivix
Seed Round in 2018
Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.